These include selective ER modulators such as tamoxifen, aromatase inhibitors like anastrozole and letrozole, and selective ER degraders such as fulvestrant, all of which have proven to be effective in treating ER+ breast cancer [3]. This evidence concerns the gene ESR1 and breast cancer.